Upadacitinib for the treatment of rheumatoid arthritis

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038.
   PubMed Web of Science ®Google Scholar
• Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica. 2010;5:286–291.
   PubMedGoogle Scholar
• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Prim. 2018;4.
   PubMed Web of Science ®Google Scholar
• van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial. Ann Intern Med. 1996;124(8):699–707.
   PubMed Web of Science ®Google Scholar
• Emery P, Solem C, Majer I, et al. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. Rheumatol Int. 2015;35(11):1837–1849.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11:276–289.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé J, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017.
   Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol. 2016;32:29–33.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521–546.
   PubMed Web of Science ®Google Scholar
• Nakayamada S, Kubo S, Iwata S, et al. Recent progress in JAK inhibitors for the treatment of Rheumatoid arthritis. BioDrugs. 2016;30(5):407–419.
   PubMed Web of Science ®Google Scholar
• Semerano L, Decker P, Clavel G, et al. Developments with investigational Janus Kinase inhibitors for rheumatoid arthritis. Expert Opin Invest Drugs. 2016;25(12):1355–1359.
   PubMed Web of Science ®Google Scholar
• Perry E, Kelly C, Eggleton P, et al. The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? Rheumatology (Oxford). 2014;53(11):1940–1950.
   PubMed Web of Science ®Google Scholar
• Derksen VFAM, Huizinga TWJ. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017;39(4):437–446.
   PubMed Web of Science ®Google Scholar
• Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196.
   PubMed Web of Science ®Google Scholar
• Holers VM. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr Opin Immunol. 2013;25(6):728–735.
   PubMed Web of Science ®Google Scholar
• Muller S, Radic M. Citrullinated autoantigens: from diagnostic markers to pathogenetic mechanisms. Clin Rev Allerg Immunol. 2015;42(2):232–239.
   Google Scholar
• Laurent L, Clavel C, Lemaire O, et al. Fcγ receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis. 2011;70(6):1052–1059.
   PubMed Web of Science ®Google Scholar
• Pratesi F, Dioni I, Tommasi C. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann Rheum Dis. 2014;73(7):1414–1422.
   PubMed Web of Science ®Google Scholar
• Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol. 2012;8(10):573–586.
   PubMed Web of Science ®Google Scholar
• Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6(15).
   Google Scholar
• Zhang Y, Wei F, Liu CJ. Overexpression of ADAMTS-7 leads to accelerated initiation and progression of collagen-induced arthritis in mice. Mol Cell Biochem. 2015;404:171–179.
   PubMed Web of Science ®Google Scholar
• Liu CJ. The role of ADAMTS-7 and ADAMTS-12 in the pathogenesis of arthritis. Nat Clin Pract Rheumatol. 2009;5(1):38–45.
   PubMedGoogle Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Hwang D, Kim WU. Modelling cytokine signalling networks. Nat Rev Rheumatol. 2017;1:5–6.
   Google Scholar
• Hammaker D, Sweeney S, Firestein GS. Signal transduction networks in rheumatoid arthritis. Ann Rheum Dis. 2003;62(2):86–89.
   PubMedGoogle Scholar
• Kumar S, Boehm J, Lee JC. P38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nature Rev Drug Discov. 2003;2:717–726.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nature Rev Drug Discov. 2003;2:473–488.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013;9(3):173–182.
   PubMed Web of Science ®Google Scholar
• Patterson H, Nibbs R, McInnes I, et al. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol. 2013;176:1–10.
   Web of Science ®Google Scholar
• Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochim Biophys Acta. 2015;1851:882–897.
   PubMed Web of Science ®Google Scholar
• Rommel C, Camps M, Ji H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol. 2007;7:191–201.
   PubMed Web of Science ®Google Scholar
• Malemud C. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10:117–127.
   PubMed Web of Science ®Google Scholar
• Malemud C. Intracellular signaling pathways in rheumatoid arthritis. J Clin Cell Immunol. 2013;4:160.
   PubMedGoogle Scholar
• Mori T, Miyamoto T, Yoshida H, et al. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol. 2011;23(11):701–712.
   PubMed Web of Science ®Google Scholar
• Farlik M, Reutterer B, Schindler C, et al. Nonconventional initiation complex assembly by STAT and NF-κB transcription factors regulates nitric oxide synthase expression. Immunity. 2010;33(1):25–34.
   PubMed Web of Science ®Google Scholar
• Yang XO, Panopoulos AD, Nurieva R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007;282(13):9358–9363.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862.
   PubMed Web of Science ®Google Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006;65(2):149–156.
   PubMed Web of Science ®Google Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment1. Ann Rheum Dis. 2006;65(2):558–1564.
   Google Scholar
• Schwartz D, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):1558–1562.
   Web of Science ®Google Scholar
• Leonard WJ, O’Shea JJ. JAKs and STATs: biological implications. Ann Rev Immunol. 1998;16:293–322.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of JAK-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–484.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012;18(11):3008–3014.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate twelve-month data from a twenty-four–month phase III randomized radiographic study. Arthritis Rheumatism. 2013;65(3):559–570.
   PubMed Web of Science ®Google Scholar
• Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587–597.
   PubMed Web of Science ®Google Scholar
• Wollenhaupt J, Silverfield J, Lee EB, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years. Arthritis Rheumatol. 2017;69(10):Abstract 522.
   Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386.
   PubMed Web of Science ®Google Scholar
• Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507.
   PubMed Web of Science ®Google Scholar
• Kremer K, Hall ZG, Li S, et al. Tofacitinib in combination with nonbiologic disease- modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253–261.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–460.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arhritis Rheumatol. 2017;69(3):506–517.
   PubMed Web of Science ®Google Scholar
• Taylor P, Keystone E, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662.
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Heijde D, Chen Y, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Clin Epidemiol Res. 2017;76(1):88–95.
   Google Scholar
• Genovese M, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheumatic Dis. 2017;76:998–1008.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheumatic Dis. 2017;76:1009–1019.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–275.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Fiorino G, Furfaro F, et al. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Invest Drugs. 2018;27(7):595–599.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Yang F, Østergaard M, et al. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. Ann Rheum Dis. 2016;75(11):1979–1983.
   PubMed Web of Science ®Google Scholar
• Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):46–55.
   PubMed Web of Science ®Google Scholar
• Telliez JB, Dowty ME, Wang L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442–3451.
   PubMed Web of Science ®Google Scholar
• Voss J, Graff C, Schwartz A, et al. Pharmacodynamics of a novel JAK1 selective inhibitors in rat arthritis and anemia models and in helathy human subjects [Abstract]. Ann Rheum Dis. 2014;73(2):222.
   Google Scholar
• Moy LY, Chiu CS, Faltus R, et al. Efficay of a novel orally bioavailable JAK1 selective compound in a preclinical rat collagen-induced arthritis model [Abstract number 2354]. In: ACR/ARHP annual meeting. 2014. Rheumatoid Arthritis - Animal Models. Available from: https://acrabstracts.org
   Google Scholar
• Clinicaltrials.gov. A study comparing ABT-494 to placebo and to adalimumab in participants with psoriatic arthritis who have an inadequate response to at least one non-biologic disease modifying anti-rheumatic drug (SELECT - PsA 1). NCT03104400, 2017.
   Google Scholar
• Clinicaltrials.gov. A study comparing ABT-494 to placebo in participants with active psoriatic arthritis who have a history of inadequate response to at least one biologic disease modifying anti-rheumatic drug (SELECT - PsA 2). NCT03104374, 2017.
   Google Scholar
• ClinicalTrials.gov. A multicenter, randomized, double-blind, placebo-controlled study of ABT-494 for the induction of symptomatic and endoscopic remission in subjects with moderately to severely active Crohn’s disease who have inadequately responded to or are intolerant to I. NCT02365649.
   Google Scholar
• Clinicaltrials.gov. A study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis. NCT02819635, 2017.
   Google Scholar
• Clinicaltrials.gov. A study to evaluate ABT-494 in adult subjects with moderate to severe atopic dermatitis. NCT02925117, 2017.
   Google Scholar
• Mohamed MF, Camp HS, Jiang P, et al. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–1558.
   PubMed Web of Science ®Google Scholar
• Klunder B, Mohamed MF, Othman AA. Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet. 2018;57(8):977–988.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Emery P, Camp HS, et al. Phase IIB study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68(12):2867–2877.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study, in patients with rheumatoid arthritis and inadequate response to methotrexate. Arthritis Rheumatol. 2016;68(12):2857–2866.
   PubMed Web of Science ®Google Scholar
• Mohamed MEF, Coppola S, Feng T, et al. Characterisation of the effect of renal impairement on Upadacitinib pharamcokinetics [Abstract]. Ann Rheum Dis. 2018;77(2):1400–1401.
   Google Scholar
• Mohamed MEF, Coppola S, Feng T, et al. Mild and moderate hepatic impairement have no clinically relevant impact on Upadacitinib pharmacokinetics: results from a dedicated phase I study [Abstract]. Ann Rheum Dis. 2018;77(2):1400.
   Google Scholar
• Mohamed ME, Jungerwirth S, Asatryan A, et al. Assessment of the effect of CYP3A inhibition, CYP induction, OATP1B inhibition and administration of high-fat meal on the pharmacokinetics of the potent and selective JAK1 inhibitor ABT-494 [Abstract]. Br J Clin Pharmacol. 2017;83(10):2242–2248.
   Google Scholar
• Mohamed MEF, Trueman S, Feng T, et al. The selective JAK1 inhibitor upadacitinib has no effect on pharmacokinetics of the hormonal contraceptives levonorgestrel and ethinylestradiol [Abstract number 506]. Arthritis Rheumatol. 2017;69(10).
   Google Scholar
• Genovese MC, Kremer J, Zhong S, et al. Long-term safety and efficacy of upadacitinib (ABT-494), an oral JAK-1 inhibitor in patients with rheumatoid arthritis in an open label extension study [Abstract]. Ann Rheumatic Dis. 2017;69(10):979.
   Google Scholar
• Klunder B, Mohamed MEF, Camp HS, et al. Exposure-response analysis of the effect of upadacitinib on ACR responses in the phase 2b rheumatoid arthritis trials in patients with inadequate response to methotrexate or to anti-tumor necrosis factor therapy [Abstract number 505]. Arthritis Rheumatol. 2017;69(10).
   Google Scholar
• Burmester GR, Kremer JM, Den Bosch V, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–2512.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleishmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–2524.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven R, Dore R, Chen K, et al. Impact of 12 weeks of upadacitinib treatment on individual and composite disease measures in patiens with rheumatoid arthritis and inadequate response to conventional synthetic and biologic dmards. Ann Rheumatic Dis. 2018;77(2):A984.
   Google Scholar
• Smolen JS, Cohen S, Emery P, et al. Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate [Abstract]. Ann Rheum Dis. 2018;77(2):A67.
   Google Scholar
• Van Vollenhoven R, Takeuchi T, Pangan AL, et al. A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-Naïve patients with active rheumatoid arthritis [Abstract number 891]. Arthtitis Rheumatol. 2018;70(10,).
   Google Scholar
• Fleischmann R, Pangan AL, Mysler E, et al. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate [Abstract number 890]. Arthritis Rheumatol. 2018;70(10).
   PubMedGoogle Scholar
• Clincaltrials.gov. [cited 2018 Oct 15]. A phase 3 study to compare upadacitinib to abatacept in subjects with rheumatoid arthritis on stable dose of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) who have inadequate response or intolerance to biologic DMARDs SELECT-CHOICE. NCT03086343, 2018.
   Google Scholar
• McInnes IB, Higgs R, Lee J, et al. Ex vivo comparison of baricitinib, upadacitinib, filgotinib and tofacitinib for cytokine signalling in human leucocyte subpopulations [Abstract]. Ann Rheum Dis. 2018;77(1).
   Google Scholar